REVA Medical Release: Richard Kimes Hired As SVP Of Operations
San Diego, California and Sydney, Australia (Wednesday, 20 January 2016, AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to announce that Richard Kimes has joined the Company as Senior Vice President of Operations. In this role he will be responsible for leading all manufacturing-related activities to support the launch of the Fantom® sirolimus-eluting bioresorbable coronary scaffold in international markets. The commercial launch of Fantom is anticipated to occur in the first half of 2017, following confirmation of positive clinical data and receipt of CE Mark approval.
Mr. Kimes has more than 25 years of experience in the medical device industry. He served as Senior Vice President of Operations for Volcano Corporation from June 2009 to May 2013, where he developed and executed the operations strategy, including the start-up of international manufacturing. Previously, he spent 18 years at Guidant Corporation (now Abbott Laboratories) where he held increasing roles of responsibility before becoming Director of Operations and Process Engineering for Drug-Eluting Stents. In this role, he was responsible for developing and implementing manufacturing operations to support clinical trials, regulatory approvals, and commercial sales. He has also held senior operations positions at mNemoscience GmbH and Elixir Medical Corporation.
“We are excited to bring Rick on board to fill this important role for the Company,” commented Ms. Reggie Groves, REVA’s Chief Executive Officer. “His strong operational expertise and demonstrated success transferring products from a clinical stage to full manufacturing make him ideally suited to lead REVA’s efforts to develop a world-class operations organization.”
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
Mr. Kimes has more than 25 years of experience in the medical device industry. He served as Senior Vice President of Operations for Volcano Corporation from June 2009 to May 2013, where he developed and executed the operations strategy, including the start-up of international manufacturing. Previously, he spent 18 years at Guidant Corporation (now Abbott Laboratories) where he held increasing roles of responsibility before becoming Director of Operations and Process Engineering for Drug-Eluting Stents. In this role, he was responsible for developing and implementing manufacturing operations to support clinical trials, regulatory approvals, and commercial sales. He has also held senior operations positions at mNemoscience GmbH and Elixir Medical Corporation.
“We are excited to bring Rick on board to fill this important role for the Company,” commented Ms. Reggie Groves, REVA’s Chief Executive Officer. “His strong operational expertise and demonstrated success transferring products from a clinical stage to full manufacturing make him ideally suited to lead REVA’s efforts to develop a world-class operations organization.”
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.